Nbea is required for the survival and proper differentiation of HSPC after transplantation. (A) Contribution of CD45.2+mCherry+ cells to recipient BM HSPCs over time after transplant, following the same experimental schematic as in Figure 1B. (B) CFU potential of mCherry+ HSPCs recovered from transplant recipients at 10 weeks after transplant. (Bi) Total CFUs. (Bii) Frequency of CFUs by size. (Biii) Frequency of CFU subtype. (C) Annexin V levels in CD45.2+mCherry+ cells in recipient BM HSPCs over time after transplant. All data are from 3 independent transplants with 5 mice per condition per transplant. Data are represented as mean ± SEM. ∗P < .05; ∗∗P < .005; ∗∗∗P < .001, relative to recipients of control-shRNA HSPCs. Ery, erythroid; G, granulocyte; M, monocyte; GM, granulocyte/monocyte; GEMM, granulocyte, erythrocyte, monocyte, and megakaryocyte.

Nbea is required for the survival and proper differentiation of HSPC after transplantation. (A) Contribution of CD45.2+mCherry+ cells to recipient BM HSPCs over time after transplant, following the same experimental schematic as in Figure 1B. (B) CFU potential of mCherry+ HSPCs recovered from transplant recipients at 10 weeks after transplant. (Bi) Total CFUs. (Bii) Frequency of CFUs by size. (Biii) Frequency of CFU subtype. (C) Annexin V levels in CD45.2+mCherry+ cells in recipient BM HSPCs over time after transplant. All data are from 3 independent transplants with 5 mice per condition per transplant. Data are represented as mean ± SEM. ∗P < .05; ∗∗P < .005; ∗∗∗P < .001, relative to recipients of control-shRNA HSPCs. Ery, erythroid; G, granulocyte; M, monocyte; GM, granulocyte/monocyte; GEMM, granulocyte, erythrocyte, monocyte, and megakaryocyte.

Close Modal

or Create an Account

Close Modal
Close Modal